Gastric Cancer Treatment Denied by Insurance: How to Appeal

Gastric (stomach) cancer is diagnosed in approximately 27,000 Americans annually, with a significant proportion presenting at advanced stages when systemic therapy is the primary treatment. The treatment landscape has changed substantially with the approvals of pembrolizumab, nivolumab, and trastuzumab for HER2-positive disease in the first-line setting, and ramucirumab in the second-line setting. Despite strong FDA approvals and NCCN support, insurance denials for gastric cancer treatment are common. Here's how to fight back.

Common Gastric Cancer Denial Scenarios

HER2 Testing

Approximately 15–20% of gastric and gastroesophageal junction (GEJ) adenocarcinomas overexpress HER2, making them eligible for trastuzumab (Herceptin) therapy. HER2 testing by IHC and/or FISH/ISH is essential for all patients with advanced gastric/GEJ adenocarcinoma and is required before trastuzumab initiation. Insurers may deny HER2 testing by:

• Classifying it as "a biomarker test not required for diagnosis" (incorrect — it guides treatment selection)
• Requiring it be repeated at an in-network laboratory when results from an out-of-network pathology lab already exist
• Denying testing in patients with earlier-stage disease where systemic therapy is being planned

Trastuzumab (Herceptin) for HER2+ Gastric Cancer

Trastuzumab in combination with cisplatin-based chemotherapy is FDA-approved for HER2-positive unresectable or metastatic gastric or GEJ adenocarcinoma. The ToGA trial established this standard. Insurers deny trastuzumab by:

• Requiring IHC 3+ (not IHC 2+/FISH amplified) for approval, despite FDA label including FISH-amplified tumors
• Denying maintenance trastuzumab after chemotherapy completion
• Applying step therapy through chemotherapy alone before approving combination trastuzumab

Ramucirumab (Cyramza)

Ramucirumab is FDA-approved as a single agent or in combination with paclitaxel for advanced gastric/GEJ adenocarcinoma that progressed on or after fluoropyrimidine/platinum chemotherapy. Insurers deny ramucirumab by:

• Calling it "investigational" for the specific line of therapy
• Requiring failure of another agent first in a sequence not supported by FDA labeling
• Denying the combination with paclitaxel versus single-agent use

Nivolumab and Pembrolizumab

Nivolumab in combination with chemotherapy (FOLFOX or CapeOX) is FDA-approved as first-line therapy for advanced gastric/GEJ/esophageal adenocarcinoma based on the CheckMate 649 trial. Pembrolizumab is approved for HER2-positive gastric cancer (first-line, with trastuzumab and chemotherapy) and for MSI-H/TMB-H tumors.

Insurers deny IO therapy for gastric cancer by:

• Requiring chemotherapy alone first before adding nivolumab, despite the first-line IO approval
• Applying incorrect CPS cutoffs — CheckMate 649 benefit was demonstrated across all CPS levels, with greater benefit at higher CPS
• Denying pembrolizumab for PD-L1 positive gastric cancer when nivolumab is preferred, or vice versa, without clinical justification

Perioperative Chemotherapy (FLOT)

For resectable gastric/GEJ adenocarcinoma, perioperative FLOT (docetaxel, oxaliplatin, leucovorin, fluorouracil) is NCCN-preferred. FLOT (4 pre-op + 4 post-op cycles surrounding surgery) reduced mortality versus ECF regimen in the FLOT4-AIO trial. Insurers may deny:

• Perioperative chemotherapy altogether, citing the surgery as "the treatment"
• FLOT specifically, requiring older regimens (ECF, ECX) instead
• Post-operative chemotherapy if surgical margins are clear

Gastrectomy Authorization

Total or subtotal gastrectomy is the standard surgical approach for resectable gastric cancer. Insurers may deny:

• D2 lymphadenectomy as "excessive" — this extended lymph node dissection is standard for curative-intent resection per NCCN
• Minimally invasive or robotic gastrectomy at experienced centers
• Reconstruction procedures (Billroth II, Roux-en-Y) as "separate" from the gastrectomy

MSI/MMR and TMB Testing

MSI-H/dMMR and TMB-H (≥ 10 mutations/megabase) gastric cancers are eligible for pembrolizumab per tumor-agnostic FDA approvals. Testing for MSI, MMR, and TMB should be standard in advanced gastric cancer. Denials of these tests limit access to immunotherapy options.

Your Legal Rights

ACA essential health benefits: Gastric cancer treatment is covered with no lifetime or annual dollar limits.

External Independent Review: Complete Guide" class="auto-link">External review: For nivolumab + chemotherapy first-line denials and ramucirumab denials, external reviewers with GI oncology expertise regularly reverse insurer decisions.

Step therapy override laws: Several states protect cancer patients from inappropriate step therapy requirements. For HER2+ gastric cancer, trastuzumab combination first-line is the only appropriate standard.

Building Your Appeal

1. Pathology report: Confirming gastric/GEJ adenocarcinoma, HER2 IHC/FISH results, MSI/MMR/TMB status
2. Staging workup: CT imaging of chest/abdomen/pelvis, endoscopy report
3. NCCN Gastric Cancer Guidelines: Cite specific first-line or perioperative regimen with evidence category
4. Relevant trial citations: CheckMate 649 (nivolumab), ToGA (trastuzumab), FLOT4-AIO (FLOT), RAINBOW (ramucirumab)
5. Letter of medical necessity: From the treating GI oncologist or gastroenterologist-oncologist

Fight Back With ClaimBack

ClaimBack helps gastric cancer patients appeal insurance denials for immunotherapy, HER2-targeted therapy, and surgery authorization. Our platform provides the structure to build a compelling, evidence-driven appeal.

Start your appeal at ClaimBack

Gastric cancer insurance denials are reversible with the right appeal. Take action today to protect your access to care.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied